Actinium Pharmaceuticals Inc. (ATNM) shares gained 3.95% in after-hours on Wednesday, September 15, 2021, and closed the daily trading at $7.10. Even in the regular trading session of Wednesday, ATNM’s stock gained 18.58%. ATNM shares have fallen 27.42% over the last 12 months, and they have moved up 12.15% in the past week. Over the past three months, the stock has lost 17.31%, while over the past six months, it has declined 24.36%.
Let’s have a look at its latest news.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
ATNM provided an update about Iomab-B
On September 15, 2021, Actinium Pharmaceuticals, Inc (ATNM) completed enrollment of the pivotal Phase 3 SIERRA trial for Iomab-B. The SIERRA trial is a 150-patient, controlled study conducted at 24 leading bone marrow transplant centres in the United States and Canada. SIERRA is the only randomized Phase 3 trial to offer bone marrow transplant (BMT) to patients with (AML) age 55 and above, which is the only curative treatment option for this patient population.
Actinium expects to present data in the fourth quarter of 2021 and to announce topline data in mid-2022. These data are expected to support the registration of a Biologics License Application (BLA) for Iomab-B.
Actinium on Russell Microcap® Index
Actinium Pharmaceuticals, Inc (ATNM) was added to the Russell Microcap® Index after the 2021 Russell indexes annual reconstitution, on June 28, according to a preliminary list of additions.
ATNM strengthened its portfolio
On June 17, 2021, a patent covering the composition and methods administration of Iomab-B was issued in the EU to Actinium Pharmaceuticals, Inc. (ATNM). The issued patent in the EU is expected to have a useful life through 2036. In addition, Actinium has been granted a patent covering the same composition and methods of administration claims in Japan.
Actinium data presentation at SNMMI
On June 15, 2021, (ATNM) presented data from its pivotal Phase 3 SIERRA Actinium Pharmaceuticals, Inc. trial for Iomab-B in an oral presentation at the 2021 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, which was held virtually from June 11th – 14th. Iomab-B is radiotherapy that targets cells expressing CD45, a protein found only on blood cancer cells and immune cells including bone marrow stem cells, with the radioisotope iodine-131 and is intended to be a targeted conditioning agent to enable potentially curative bone marrow transplant (BMT).
Conclusion
The recent update about the trial of Iomab-B was the reason behind its surge in the after-hours on Wednesday and it can continue its momentum on Thursday as well.